Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Mild-to-Moderate Chronic Plaque Psoriasis
NCT03131570Phase 2Completed
- Start
- May 2017
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing Secukinumab with Placebo -> Secukinumab (2 arms). Primary endpoint: Percentage of Subjects Who Have 75% or More Reduction in Psoriasis Area-and-severity Index at 12 weeks. Started May 2017; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03131570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131570.